請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15554完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳秀熙(HSIU-HSI CHEN) | |
| dc.contributor.author | YU-CHING WANG | en |
| dc.contributor.author | 王毓璟 | zh_TW |
| dc.date.accessioned | 2021-06-07T17:47:51Z | - |
| dc.date.copyright | 2020-08-27 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-10 | |
| dc.identifier.citation | [1]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. [2]Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99:E276–285. [3]Albores-Saavedra J, Henson DE, Glazer E, et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7. [4]Forman D, Bray F, Brewster DH, et al. Cancer incidence in five continents volume X. Scientific Publications. IARC, Lyon. 2014. [5]Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer. 2016;139:2436-2446. [6]Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115:3801–3807. [7]Ceresini G, Corcione L, Michiara M, et al. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009. Cancer. 2012;118:5473–5480. [8]Delellis RA, Lloyd RV, Heitx P. Pathology and genetics of tumors of endocrine organs. In World Health Organization of Tumors. IARC, Lyon. 2004;73–76. [9]Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017;77:140–152. [10]Lin JD, Hsueh C, Chao TC. Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis. Medicine. 2015;94(26):e1063. [11]Wang TS, Cheung K, Farrokhyar F, et al. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20:3477–3483. [12]Ito Y, Masuoka H, Fukushima M, et al. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J. 2010;57:523–531. [13]林口長庚醫院甲狀腺癌醫療團隊. '甲狀腺癌衛教手冊'. 2011. [14]Lundgren CI, Hall P, Dickman PW, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106:524–31. [15]Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172:692–4. [16]Wang Q, Chu B, Zhu J, et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma. Clin Transl Oncol. 2014;16:44–8. [17]Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85(2):252–254. [18]American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. [19]Goropoulos A, Karamoshos K, Christodoulou A, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2004;28(12):1275–1281. [20]Zhu YX, Wang HS, Wu Y, et al. Whether VI region lymph nodes belong to primary site of the thyroid carcinoma or lateral cervical lymph node metastases. Chin J Surg. 2004;42(14):867–869. [21]Wang XL. Diagnosis and treatment of thyroid cancer. Chin J Otorhinolaryngol Head Neck Surg. 2009;44(04): 349-352. [22]Moreno MA, Agarwal G, de Luna R, et al. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2011;137(2):157–162. [23]Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–1428. [24]Lim YS, Lee JC, Lee YS, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150(1):116–121. [25]Patron V, Hitier M, Bedfert C, et al. Predictive factors for lateral occult lymph node metastasis in papillary thyroid carcinoma. Eur Arch Otorhinolaryngol. 2013;270(7):2095–2100. [26]Shi RL, Qu N, Yang SW, et al. Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model. Onco Targets Ther. 2016;9:5015–5022. [27]Wu MH, Shen WT, Gosnell J, et al. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Head Neck. 2015;37(9):1336–1343. [28]Pathak KA, Lambert P, Nason RW, et al. Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. Eur J Surg Oncol. 2016;42(10):1491–1496. [29]Kim HI, Kim K, Park SY, et al. Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis. Oral Oncology. 2018;78:80–86. [30]Cho E, Kim E, Moon HJ, et al. High suspicion US pattern on the ATA guidelines, not cytologic diagnosis, maybe a predicting marker of lymph node metastasis in patients with classical papillary thyroid carcinoma. Am J Surg. 2018;216(3):562-566. [31]Lin DZ, Qu N, Shi RL, et al. Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma. Onco Targets Ther. 2016;9:5307–5316. [32]Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9–13. [33]Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15(6):816–823. [34]Roques F, Michel P, Goldstone AR, et al. The logistic EuroSCORE. Eur Heart J. 2003;24(9):881-882. [35]Michel P, Roques F, Nashef SA; EuroSCORE Project Group. Logistic or additive EuroSCORE for high-risk patients?. Eur J Cardiothorac Surg. 2003;23(5):684–687. [36]Ge YP, Li CN, Chen L, et al. Preliminary exploration of mathematical model in predicting the prognosis of Chinese people undergoing aortic surgery. Chinese Journal of Thoracic and Cardiovascular Surgery. 2015;31(8):481–485. [37]Yap C, Reid C, Yii M, et al. Validation of the EuroSCORE model in Australia. Eur J Cardiothorac Surg. 2006;29(4):441–446. [38]Li HP, Wang L, Yang YJ, et al. The Establishment and Evaluation of Scoring System for Predicting the Risk of Postoperative Breast Cancer-related Lymphedema. Chinese General Practice. 2014;17(18):2056–2061. [39]Jin R, Grunkemeier GL; Providence Health System Cardiovascular Study Group. Additive vs. logistic risk models for cardiac surgery mortality. Eur J Cardiothorac Surg. 2005;28(2):240-243. [40]Liu FH, Kuo SF, Hsueh C, et al. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol. 2015;112(2):149–154. [41]Kim E, Choi JY, Koo do H, et al. Differences in the characteristics of papillary thyroid microcarcinoma ≤5mm and >5mm in diameter. Head Neck. 2015;37(5):694–697. [42]Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma: clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest. 2012;42(6):657–64. [43]Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–954. [44]Gu ZQ, Shan CX, Liu J, et al. Patterns and predictive factors of central lymph node metastasis in cN0 papillary thyroid carcinoma. Acad J Sec Mil Med Univ. 2016;37: 544–547. [45]Unal I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Comput Math Methods Med. 2017;2017:3762651. [46]Moon HJ, Kwak JY, Kim EK, et al. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol. 2009;16:3125–31. [47]Lee DW, Ji YB, Sung ES, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013;39:191–6. [48]Liu W, Cheng RC, Su YJ, et al. Surgical planning and rational analysis of cN0 papillary thyroid carcinoma for 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Chinese Journal of Practical Surgery. 2017,37(5):568–571. [49]Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. [50]Chéreau N, Buffet C, Trésallet C, et al. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management. Surgery. 2016;159(3):755–762. [51]Liu W, Cheng RC, Su YJ, et al. Predictive factors of rⅥb metastasis and the correlation between rⅥa and rⅥb metastasis in papillary thyroid microcarcinoma. Chinese Journal of Practical Surgery. 2017;37(9):1007–1012. [52]NCCN. 'The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology (Version 2)'. May 17, 2017. [53]Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. [54]Gharib H, Papini E, Garber IR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules-2016 update. Endocr Pract. 2016;22(5):622–639. [55]Lee DW, Ji YB, Sung ES, et al. Roles of ultrasonography and computed to mography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013;39(2):191–196. [56]Khokhar M T, Day KM, Sangal RB, et al. Preoperative high-resolution ultrasound for the assessment of malignant central compartment lymph nodes in papillary thyroid cancer. Thyroid. 2015;25(12):1351–1354. [57]Mazzaferri EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab. Apr 2009;94(4):1086–8. [58]Liu W, Yan XJ, Cheng RC, et al. Progress of early detection of hypocalcemia after thyroid surgery. Chinese Journal of Practical Surgery. 2016;36(11):1234–1237. [59]Mao LN, Wang P, Li ZY, et al. Risk factor analysis for central nodal metastasis in papillary thyroid carcinoma. Oncol Lett. 2015;9(1): 103–107. [60]Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97(4):1250–1257. [61]Nam IC, Park JO, Joo YH, et al. Patern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: a prospective study. Head Neck. 2013;35(1):40–45. [62]Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27–34. [63]Ma B, Wang Y, Yang S, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Surg. 2016;28:153–161. [64]Oh HS, Park S, Kim M, et al. Young age and male sex are predictors of large-volume central neck lymph node metastasis in clinical N0 papillary thyroid microcarcinomas. Thyroid. 2017;27(10):1285–1290. [65]Zhao C, Jiang W, Gao Y, et al. Risk factors for lymph node metastasis (LNM) in patients with papillary thyroid microcarcinoma (PTMC): role of preoperative ultrasound. J Int Med Res. 2017;45(3):1221–1230. [66]Zhang LY, Liu ZW, Liu YW, et al. Risk factors for nodal metastasis in cN0 papillary thyroid microcarcinoma. Asian Pac J Cancer Prev. 2015;16(8):3361–3363. [67]Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg. 2011;35(2):318–323. [68]Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34(6):1222–1231. [69]Lundgren CI, Hall P, Dickman PW, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–531. [70]Baek SK, Jung KY, Kang SM, et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20(2):147–152. [71]Li X, Zhao C, Hu D, et al. Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma. Oncol Lett. 2013;5(4):1412–1416. [72]Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013;20(7):2266–2273. [73]Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer. 2016;22(2):198–206. [74]Liu Z, Wang L, Yi P, et al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol. 2014;7(3):932–937. [75]Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116(6):1036–1041. [76]Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012; 118(8):2069–2077. [77]Jiang LH, Yin KX, Wen QL, et al. Predictive Risk-scoring Model For Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. Sci Rep. 2020;10(1):710. [78]Ma WQ, Zhou P, Liang YP, et al. Preliminary construction of risk scoring system for estimation of central cervical lymph node metastasis in papillary thyroid microcarcinoma. Chin J Gen Surg. 2018;27(6):752–760. [79]Chen L, Wu YH, Lee CH, et al. Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. World J Surg. 2018;42(9):2846–2857. [80]Liao LJ, Hsu WL, Wang CT, et al. Analysis of sentinel node biopsy combined with other diagnostic tools in staging cN0 head and neck cancer: A diagnostic meta-analysis. Head Neck. 2016;38(4):628–634. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15554 | - |
| dc.description.abstract | 目的：透過乳突狀甲狀腺癌臨床資料建構中央區頸部淋巴結轉移之羅吉斯迴歸預測模型及風險評分系統。 方法：採用回溯性研究方法，對1984年至2018年間在林口長庚紀念醫院初次行甲狀腺全摘除及中央區淋巴結清除術之650位甲狀腺乳突癌患者臨床資料進行單因子分析與多變量羅吉斯迴歸模型，以探討和確定危險因素。然後，透過迴歸分析建立Logistic評分系統和Additive評分系統，以預測發生中央區頸部淋巴結轉移的風險。 結果：我們的結果顯示，年齡、性別、腫瘤大小及病灶多灶性為甲狀腺乳突癌中央區淋巴結轉移相關危險因子。Logistic評分系統分數為2分時，敏感度為51.3%，特異性為70.4%，陽性預測值為66.8%，陰性預測值為55.5%，ROC曲線下面積（AUC）為0.646（95% CI = 0.606-0.686）。Additive評分系統分數為4.1分時，敏感度為53.0%，特異性為67.1%，陽性預測值為65.1%，陰性預測值為55.2%，AUC為0.645（95% CI = 0.605-0.685）。Logistic評分系統及Additive評分系統透過Hosmer-Lemeshow goodness-of-fit檢定結果分別為 χ2=6.379（P=0.496）、χ2=9.941（P=0.077）。 結論：我們的發現表明，疑似中央區頸部淋巴結轉移之甲狀腺乳突癌患者可透過年齡、性別、腫瘤大小及病灶多灶性來預測淋巴結轉移風險。研究結果，當估算患者相對應之Logistic評分系統score ≥2分或Additive評分系統score ≥4.1分時，則該病患對於中央區頸部淋巴結轉移屬高風險，應考慮及時接受手術。但兩評分系統的鑑別力不佳，期許未來資料庫可增加相關變項資料，例如甲狀腺超音波影像臨床特徵或BRAF基因檢測，以提升兩個評分系統效度，並為乳突狀甲狀腺癌治療計劃提供量化依據，便於臨床醫師參考。 | zh_TW |
| dc.description.abstract | Objective: To construct a Logistic regression prediction model and risk scoring system for central cervical lymph node metastasis using clinical data of papillary thyroid carcinoma. Methods: A retrospective study was conducted using the clinical data of 650 patients with papillary thyroid carcinoma who underwent total thyroidectomy and lymph node dissection in the Linkou Chang Gung Memorial Hospital between 1984 and 2018. Univariate analysis and multivariate logistic model were applied to explore and define the risk factors, followed by regression analysis to establish the Logistic scoring system and the Additive scoring system in order to predict the risk of central cervical lymph node metastasis. Results: Our results showed age, gender, tumor size, and multifocality are risk factors for central cervical lymph node metastasis of papillary thyroid carcinoma. When the score derived from the Logistic scoring system reached 2, the sensitivity was 51.3%, the specificity was 70.4%, the positive predictive value (PPV) was 66.8%, the negative predictive value (NPV) was 55.5%, and the area under the curve (AUC) was 0.646 (95% CI=0.606-0.686). When the score derived from the Additive score system reached 4.1, the sensitivity was 53.0%, the specificity was 67.1%, the PPV was 65.1%, the NPV was 55.2%, and the AUC was 0.645 (95% CI=0.605-0.685). The results of the Logistic scoring system and the Additive scoring system through Hosmer-Lemeshow goodness-of-fit test were χ2=6.379 (P=0.496) and χ2=9.941 (P=0.077). Conclusion: Our findings suggest that the risk of lymph node metastasis in patients with papillary thyroid carcinoma who are suspected of central cervical lymph node metastasis could be predicted by their age, gender, tumor size, and multifocality. According to our results, when patients’ corresponding Logistic scoring system score is greater than or equal to 2 or the Additive scoring system score is greater than or equal to 4.1, they have a higher risk for central cervical lymph node metastasis and should be considered for surgery. However, the discrimination of the two scoring systems were not good. Our findings suggest that future databases can acquire additional variables such as clinical features of thyroid ultrasound imaging or BRAF (B-Raf proto-oncogene) genetic test to improve the effectiveness of the two scoring systems and provide a quantitative basis for the treatment plan of papillary thyroid cancer. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T17:47:51Z (GMT). No. of bitstreams: 1 U0001-0408202010343800.pdf: 4349451 bytes, checksum: fdf4840bfda0ee42e216ed474441bc38 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 第 1 章 導論...1 1.1 實習單位特色與簡介...1 1.1.1 甲狀腺癌臨床資料庫...2 1.1.2 乳突狀甲狀腺癌資料庫...3 1.2 甲狀腺癌...3 1.2.1 甲狀腺的構造及功能...5 1.2.2 甲狀腺癌分類...6 1.2.3 甲狀腺癌的主要症狀...7 1.2.4 甲狀腺癌的診斷方法...8 1.3 淋巴結清除術...10 1.3.1 中央區淋巴結...10 1.3.2 側頸區淋巴結...10 1.3.3 治療性中央區淋巴結清除術...11 1.3.4 預防性中央區淋巴結清除術...11 1.4 研究目的...12 1.5 文獻回顧...13 1.5.1 現階段國外已有預測PTC淋巴結轉移模型之比較...13 1.5.2 PTC風險評分模型原理...14 第 2 章 材料與方法...16 2.1 研究設計...16 2.2 納入條件與排除條件...18 2.3 研究變項...18 2.4 結果定義...19 2.5 統計方法...19 第 3 章 結果...21 3.1 PTC患者中央區頸部淋巴結轉移之單因子分析...23 3.2 PTC患者中央區頸部淋巴結轉移之多因子分析...25 3.3 風險預測評分系統...27 第 4 章 討論...31 4.1 CLNM的相關因子...32 4.1.1 性別和年齡...32 4.1.2 腫瘤大小...32 4.1.3 病灶多灶性...33 4.2 效能評價...33 第 5 章 研究限制...38 第 6 章 結論...38 MPH Foundational Competencies Checklist...39 參考文獻...46 | |
| dc.language.iso | zh-TW | |
| dc.subject | 風險評分系統 | zh_TW |
| dc.subject | 羅吉斯迴歸模型 | zh_TW |
| dc.subject | 乳突狀甲狀腺癌 | zh_TW |
| dc.subject | 中央區頸部淋巴結轉移 | zh_TW |
| dc.subject | 危險因子 | zh_TW |
| dc.subject | Central cervical lymph node metastasis | en |
| dc.subject | Risk factors | en |
| dc.subject | Risk scoring system | en |
| dc.subject | Logistic regression model | en |
| dc.subject | Papillary thyroid carcinoma | en |
| dc.title | 乳突狀甲狀腺癌中央區頸部淋巴結轉移預測模型及風險評分系統之建立 | zh_TW |
| dc.title | Establishment of Predictive Model and Risk Scoring System for the Metastasis of Central Cervical Lymph Node in Papillary Thyroid Carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林樹福(SHU-FU LIN),陳其欣(CHI-HSIN CHEN) | |
| dc.subject.keyword | 乳突狀甲狀腺癌,中央區頸部淋巴結轉移,羅吉斯迴歸模型,風險評分系統,危險因子, | zh_TW |
| dc.subject.keyword | Papillary thyroid carcinoma,Central cervical lymph node metastasis,Logistic regression model,Risk scoring system,Risk factors, | en |
| dc.relation.page | 55 | |
| dc.identifier.doi | 10.6342/NTU202002344 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-08-11 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 公共衛生碩士學位學程 | zh_TW |
| 顯示於系所單位： | 公共衛生碩士學位學程 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0408202010343800.pdf 未授權公開取用 | 4.25 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。